Meeting
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
Authors
Mohamed Shanshal
Mayo Clinic, Rochester, MN
Mohamed Shanshal , Nathan R. Foster , Yanyan Lou , Yujie Zhao , Mahesh Seetharam , Aaron Scott Mansfield , Konstantinos Leventakos , Mojun Zhu , Kimberly O. Steinert , Elizabeth Mikula , Qian Shi , Sani Haider Kizilbash , Haidong Dong , Alex A. Adjei , Wen Wee Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04007744
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9093)
DOI
10.1200/JCO.2023.41.16_suppl.9093
Abstract #
9093
Poster Bd #
81
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2023 ASCO Annual Meeting
A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.
First Author: Jordi Rodon Ahnert
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang